Drug Profile
Research programme: RNA-based antiviral therapeutics - Sarepta Therapeutics
Alternative Names: Anti-IL-10 PMO; AVI-6001; AVI-6006; AVI-7012; NeuGene antiviral antisense compounds; NP AUG PMO; PB2 AUG PMO; Viral PMO-X for dengue - Sarepta TherapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AVI BioPharma
- Developer Sarepta Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action Genetic transcription inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dengue; HIV infections; Influenza virus infections; Junin virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Dengue in USA (Parenteral)
- 16 Apr 2013 Research in therapies for Dengue is ongoing in USA
- 16 Apr 2013 No development reported - Preclinical for HIV infections in USA (Parenteral)